Article

Lentivirus for CAR-T and Other Cell Therapy Products: A Microbiological and Biosafety Perspective

2025-09-12

Abstract excerpt

Chimeric antigen receptor T cell (CAR-T) therapy is a significant and costly immunotherapy strategy that has provided benefits to many patients with cancer and autoimmune diseases. As of January 2025, only a few FDA- and NMPA-approved CAR-T therapies were available for clinical use, targeting CD19 or B cell maturation antigen (BCMA) on cancer cells. The manufacturing process for these approved CAR-T cells mainly r...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c5b71440-a906-582c-815f-c98ba16a812c
DOI: 10.20944/preprints202509.1093.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Lentivirus for CAR-T and Other Cell Therapy Products: A Microbiological and Biosafety PerspectiveDOI 10.20944/preprints202509.1093.v1Read

Lentiviral Vectors for CAR-T and Other Cell Therapy Products: A Microbiological and Biosafety PerspectiveSemantic proximity Read

Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospectsSemantic proximity Read

Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology PatientsSemantic proximity Read

Clinical use of lentiviral vectorsSemantic proximity Read

Delivering genes with human immunodeficiency virus-derived vehicles: still state-of-the-art after 25 yearsSemantic proximity Read

Review: Sustainable Clinical Development of CAR-T Cells – Switching From Viral Transduction Towards CRISPR-Cas Gene EditingSemantic proximity Read

Revolutionizing CAR T Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and AccessibilitySemantic proximity Read

Current Non-Viral-Based Strategies to Manufacture CAR-T CellsSemantic proximity Read

Engineering of CAR-less lentiviral vectors via ER retention-mediated CAR blockadeSemantic proximity Read

Lentiviral vector packaging and producer cell lines yield titers equivalent to the industry-standard four-plasmid processSemantic proximity Read

Engineering strategies to safely drive CAR T-cells into the futureSemantic proximity Read

Past, Present, and Future of Viral Vector Vaccine Platforms: A Comprehensive ReviewSemantic proximity Read